Dengue vaccines: Preparing to roll back dengue

Current Opinion in Investigational Drugs

Volumn 4, Issue 2, 2003, Pages 168-171

  Jacobs, Michael ^a   Young, Paul ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Dengue fever; Dengue hemorrhagic fever; DNA vaccines; Flavivirus; Subunit vaccines; Tetravalent live attenuated vaccines

Indexed keywords

CHIMERIVAX DENGUE; DENGUE VACCINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SUBUNIT DENGUE VACCINE; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT ENHANCEMENT; BIOTECHNOLOGY; CLINICAL TRIAL; DENGUE; DENGUE VIRUS; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; INFECTION CONTROL; INFECTION RISK; MOLECULAR BIOLOGY; NONHUMAN; PREVALENCE; REVIEW; SEROCONVERSION; SEROTYPE; SIDE EFFECT; VACCINE PRODUCTION; VIRUS ATTENUATION; WORLD HEALTH ORGANIZATION; YELLOW FEVER;

ANIMALS; ANTIBODIES, VIRAL; DENGUE; DRUG EVALUATION, PRECLINICAL; HUMANS; SEROTYPING; VACCINES, ATTENUATED; VACCINES, DNA; VIRAL VACCINES;

EID: 0037303587     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Jacobs M: Dengue: Emergence as a global public health problem and prospects for control. Trans R Soc Trop Med Hyg (2000) 94(1):7-8.
2. Halstead SB: Pathogenesis of dengue: Challenges to molecular biology. Science (1988) 239(4839):476-481. A seminal commentary that stimulated research applying modern molecular technology to the development of dengue vaccines.
3. Halstead SB, Deen J: The future of dengue vaccines. Lancet (2002) 360(9341):1243-1245. An expert overview of the current state of development of dengue vaccines.
4. Almond J, Clemens J, Engers H, Halstead S, Khiem HB, Pablos-Mendez A, Pervikov Y, Tram TT: Accelerating the development and introduction of a dengue vaccine for poor children, 5-8 December 2001, Ho Chi Minh City, Vietnam. Vaccine (2002) 20(25-26):3043-3046. This reports a meeting that led to the creation of the Pediatric Dengue Vaccine Initiative and which may therefore have far-reaching implications for future progress in the development of dengue vaccines. Hopefully, history will view this as the start of a model international collaboration between key stakeholders that ultimately yielded huge success in dengue control.
5. Sabin AB, Schlesinger RW: Production of immunity to dengue with virus modified by propagation in mice. Science (1945) 101:640-642.
6. Kochel TJ, Watts DM, Halstead SB, Hayes CG, Espinoza A, Felices V, Caceda R, Bautista CT, Montoya Y, Douglas S, Russell KL: Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet (2002) 360(9329):310-312.
7. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak A: Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis (2000) 181(1):2-9. An extraordinarily intensive study that showed the association between peak viremia and dengue disease severity in humans, which is a key observation in understanding disease pathogenesis.
8. Libraty DH, Endy TP, Houng HS, Green S, Kalayanarooj S, Suntayakorn S, Chansiriwongs W, Vaughn DW, Nisalak A, Ennis FA, Rothman AL: Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis (2002) 185(9):1213-1221.
9. Rico-Hesse R, Harrison LM, Salas RA, Tovar D, Nisalak A, Ramos C, Boshell J, De Mesa MT, Nogueira RM, Da Rosa AT: Origins of dengue type-2 viruses associated with increased pathogenicity in the Americas. Virology (1997) 230(2):244-251.
10. Watts DM, Porter KR, Putvatana P, Vasquez B, Calampa C, Hayes CG, Halstead SB: Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet (1999) 354(9188):1431-1434.
11. Halstead SB, Streit TG, Lafontant JG, Putvatana R, Russell K, Sun W, Kanesa-Thasan N, Hayes CG, Watts DM: Haiti: Absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am J Trop Med Hyg (2001) 65(3):180-183.
12. Churdboonchart V, Bhamarapravati N, Peampramprecha S, Sirinavin S: Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am J Trop Med Hyg (1991) 44(5):481-493.
13. Greene S, Kurane I, Pincus S, Paoletti E, Ennis FA: Recognition of dengue virus NS1-NS2a proteins by human CD4+ cytotoxic T-lymphocyte clones. Virology (1997) 234(2):383-386.
14. Okamoto Y, Kurane I, Leporati AM, Ennis FA: Definition of the region on NS3 which contains multiple epitopes recognized by dengue virus serotype-cross-reactive and flavivirus-cross-reactive, HLA-DPw2-restricted CD4+ T-cell clones. J Gen Virol (1998) 79(Pt 4):697-704.
15. Huang CY, Butrapet S, Pierro DJ, Chang GJ, Hunt AR, Bhamarapravati N, Gubler DJ, Kinney RM: Chimeric dengue type-2 (vaccine strain PDK-53)/dengue type-1 virus as a potential candidate dengue type-1 virus vaccine. J Virol (2000) 74(7):3020-308.
16. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ, Elkins WR, Chanock RM et al: Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg (2001) 65(5):405-413.
17. Markoff L, Pang X, Houng H, Falgout B, Olsen E, Polo S: Derivation and characterization of a dengue type-1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys. J Virol (2002) 76(7):3318-3328.
18. Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Draper K, Monath TP: Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: Genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology (2002) 298(1):146-159. This paper describes the most detailed of immunogenicity of a live-attenuated tetravalent dengue vaccine.
19. Porter KR, Kochel TJ, Wu SJ, Raviprakash K, Phillips I, Hayes CG: Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses. Arch Virol (1998) 143(5):997-1003.
20. Kochel TJ, Raviprakash K, Hayes CG, Watts DM, Russell KL, Gozalo AS, Phillips IA, Ewing DF, Murphy GS, Porter KR: A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine (2000) 18(27):3166-3173.
21. Raviprakash K, Porter KR, Kochel TJ, Ewing D, Simmons M, Phillips I, Murphy GS, Weiss WR, Hayes CG. Dengue virus type-1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol (2002) 81(Pt 7):1659-1667.
22. Raviprakash K, Marques E, Ewing D, Lu Y, Phillips I, Porter KR, Kochel TJ, August TJ, Hayes CG, Murphy GS: Synergistic neutralizing antibody response to a dengue virus type-2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF. Virology (2001) 290(1):74-82. A fascinating study that demonstrates the potential for DNA vaccination that is both immunogenic and immunodulatory.
23. Whalen RG, Kaiwar R, Soong NW, Punnonen J: DNA shuffling and vaccines. Curr Opin Mol Ther (2001) 3(1):31-36.
24. Shu PY, Chen LK, Chang SF, Yueh YY, Chow L, Chien LJ, Chin C, Lin TH, Huang JH: Dengue NS1-specific antibody responses: Isotype distribution and serotyping in patients with Dengue fever and Dengue hemorrhagic fever. J Med Virol (2000) 62(2):224-232.
25. Falconar AK: The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: Potential implications in haemorrhagic fever pathogenesis. Arch Virol (1997) 142(5):897-916.
26. Jacobs MG, Robinson PJ, Bletchly C, Mackenzie JM, Young PR: Dengue virus nonstructural protein 1 is expressed in a glycosylphosphatidylinositol-linked form that is capable of signal transduction. FASEB J (2000) 14(11):1603-1610.
27. Lin CF, Lei HY, Shiau AL, Liu HS, Yeh TM, Chen SH, Liu CC, Chiu SC, Lin YS: Endothelial cell apoptosis induced by antibodies against dengue virus nonstructural protein 1 via production of nitric oxide. J Immunol (2002) 169(2):657-664.
28. Huang KJ, Li SY, Chen SC, Liu HS, Lin YS, Yeh TM, Liu CC, Lei HY: Manifestation of thrombocytopenia in dengue-2-virus-infected mice. J Gen Virol (2000) 81(Pt9):2177-2182.
29. Lin YL, Liao CL, Chen LK, Yeh CT, Liu CI, Ma SH, Huang YY, Huang YL, Kao CL, King CC: Study of Dengue virus infection in SCID mice engrafted with human K562 cells. J Virol (1998) 72(12):9729-9737.
30. An J, Kimura-Kuroda J, Hirabayashi Y, Yasui K. Development of a novel mouse model for dengue virus infection. Virology (1999) 263(1):70-77.
31. Blaney JE Jr, Johnson DH, Manipon GG, Firestone CY, Hanson CT, Murphy BR, Whitehead SS: Genetic basis of attenuation of dengue virus type-4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology (2002) 300(1):125-139.
32. The Pediatric Dengue Vaccine Initiative (2002). http://www.pdvi.org